Drug Trial Radar · NCT05158296
Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
Last checked: Nov 20, 2026Latest source record: Jul 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
7
Actual
Start
Dec 8, 2021
Primary completion
Oct 12, 2022
Study completion Oct 12, 2022
Sponsor
- Lead sponsor
- Laboratoires TheaIndustry
- Sponsor type
- Industry
- Collaborators
- Sepul Bio
- First posted
- Dec 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
Conditions
- Retinitis Pigmentosa
- Usher Syndrome Type 2
- Deaf Blind
- Retinal Disease
- Eye Diseases
- Eye Diseases, Hereditary
- Eye Disorders Congenital
- Vision Disorders
Interventions
UltevursenDrug
RNA antisense oligonucleotide for intravitreal injection
Sham-procedureOther
Sham-procedure (no experimental drug administered)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)Time frame: 18 months of treatment versus sham-procedure
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Shiley Eye Institute - UC San Diego
San Diego, California
University of California, San Francisco
San Francisco, California
University of Miami, Bascom Palmer Eye Institute
Miami, Florida
Emory Eye Center
Atlanta, Georgia
Wilmer Eye Institute, Johns Hopkins Hospital
Baltimore, Maryland
Center for Clinical Research Operations, Massachusetts Eye and Ear
Boston, Massachusetts
University of Michigan, Kellogg Eye Center
Ann Arbor, Michigan
Columbia University
New York, New York
Retina Foundation of the Southwest
Dallas, Texas
University of Wisconsin - Madison
Madison, Wisconsin
Universitaetsklinikum Tuebingen Department für Augenheilkunde
Tübingen, Germany
RadboudUMC
Nijmegen, Netherlands
Het Oogziekenhuis Rotterdam
Rotterdam, Netherlands
Moorfields Eye Hospital
London, United Kingdom
Oxford Eye Hospital
Headington, Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.